Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects

  • Bioorg Med Chem. 2021 Jan 1:29:115897. doi: 10.1016/j.bmc.2020.115897.
Rawan M Sbenati  1 ,  Mohammad H Semreen  2 ,  Ahlam M Semreen  3 ,  Mahmoud K Shehata  3 ,  Fai M Alsaghir  3 ,  Mohammed I El-Gamal  4
Affiliations
  • 1. Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates.
  • 2. Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
  • 3. Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates.
  • 4. Sharjah Institute for Medical Research, University of Sharjah, Sharjah 27272, United Arab Emirates; Department of Medicinal Chemistry, College of Pharmacy, University of Sharjah, Sharjah 27272, United Arab Emirates; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura 35516, Egypt. Electronic address: [email protected].
PMID: 33316752 DOI: 10.1016/j.bmc.2020.115897
Abstract

Several reports have highlighted imidazo[2,1-b]thiazole derivatives as potential antiproliferative agents. They act through kinase inhibition, tubulin inhibition, and Other molecular mechanisms of action. In the current article, we reviewed the imidazo[2,1-b]thiazole-based compounds that were reported as Anticancer agents. Their biological characteristics as well as structure-activity relationship (SAR) have been reviewed and evaluated. Our main focus was on the reports published in the literature from 2011 to 2020.

Keywords
Anticancer; Antiproliferative; Imidazo[2,1-b]thiazole; Imidazothiazole; Kinase inhibitor; Tubulin.